These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24039859)

  • 1. Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease.
    Vansaun MN; Mendonsa AM; Lee Gorden D
    PLoS One; 2013; 8(9):e73054. PubMed ID: 24039859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma.
    Wright JH; Johnson MM; Shimizu-Albergine M; Bauer RL; Hayes BJ; Surapisitchat J; Hudkins KL; Riehle KJ; Johnson SC; Yeh MM; Bammler TK; Beyer RP; Gilbertson DG; Alpers CE; Fausto N; Campbell JS
    Int J Cancer; 2014 Feb; 134(4):778-88. PubMed ID: 23929039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice.
    Ma KL; Ruan XZ; Powis SH; Chen Y; Moorhead JF; Varghese Z
    Hepatology; 2008 Sep; 48(3):770-81. PubMed ID: 18752326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.
    Clarke JD; Novak P; Lake AD; Shipkova P; Aranibar N; Robertson D; Severson PL; Reily MD; Futscher BW; Lehman-McKeeman LD; Cherrington NJ
    Dig Dis Sci; 2014 Feb; 59(2):365-74. PubMed ID: 24048683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.
    Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ankaflavin ameliorates steatotic liver ischemia-reperfusion injury in mice.
    Yang HJ; Tang LM; Zhou XJ; Qian J; Zhu J; Lu L; Wang XH
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):619-25. PubMed ID: 26663010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
    Shi SY; Luk CT; Schroer SA; Kim MJ; Dodington DW; Sivasubramaniyam T; Lin L; Cai EP; Lu SY; Wagner KU; Bazinet RP; Woo M
    J Biol Chem; 2017 Mar; 292(9):3789-3799. PubMed ID: 28100771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.
    Sobolewski C; Abegg D; Berthou F; Dolicka D; Calo N; Sempoux C; Fournier M; Maeder C; Ay AS; Clavien PA; Humar B; Dufour JF; Adibekian A; Foti M
    Gut; 2020 Oct; 69(10):1841-1854. PubMed ID: 31919231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.
    Ma C; Zhang Q; Greten TF
    FEBS J; 2018 Feb; 285(4):752-762. PubMed ID: 28857485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deranged hepatocyte intracellular Ca
    Ali ES; Rychkov GY; Barritt GJ
    Cell Calcium; 2019 Sep; 82():102057. PubMed ID: 31401389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of CDK4 Triggers Development of Non-alcoholic Fatty Liver Disease.
    Jin J; Valanejad L; Nguyen TP; Lewis K; Wright M; Cast A; Stock L; Timchenko L; Timchenko NA
    Cell Rep; 2016 Jul; 16(3):744-56. PubMed ID: 27373160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back.
    Yilmaz Y; Colak Y; Kurt R; Senates E; Eren F
    Tumori; 2013; 99(1):10-6. PubMed ID: 23548993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis.
    Semba T; Nishimura M; Nishimura S; Ohara O; Ishige T; Ohno S; Nonaka K; Sogawa K; Satoh M; Sawai S; Matsushita K; Imazeki F; Yokosuka O; Nomura F
    BMC Gastroenterol; 2013 Jul; 13():120. PubMed ID: 23875831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatty liver creates a pro-metastatic microenvironment for hepatocellular carcinoma through activation of hepatic stellate cells.
    Mikuriya Y; Tashiro H; Kuroda S; Nambu J; Kobayashi T; Amano H; Tanaka Y; Ohdan H
    Int J Cancer; 2015 Feb; 136(4):E3-13. PubMed ID: 25053237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microcirculatory disturbances and cellular changes during progression of hepatic steatosis to liver tumors.
    Liebig M; Hassanzada A; Kämmerling M; Genz B; Vollmar B; Abshagen K
    Exp Biol Med (Maywood); 2018 Jan; 243(1):1-12. PubMed ID: 29065724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease.
    Chavez-Tapia NC; Rosso N; Tiribelli C
    BMC Gastroenterol; 2012 Mar; 12():20. PubMed ID: 22380754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis.
    Ju L; Sun Y; Xue H; Chen L; Gu C; Shao J; Lu R; Luo X; Wei J; Ma X; Bian Z
    Sci Rep; 2020 Feb; 10(1):3201. PubMed ID: 32081971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.